JAK2 and diabetic kidney disease: An ongoing phase II RCT is testing the JAK1 and JAK2 inhibitor baricitinib as add-on to RAS blockade in patients with DKD (NCT01683409) while another will explore the JAK2/FLT3 inhibitor pacritinib in patients with refractory CRC and KRAS mutations (NCT02277093).